Glucophage XR Shortage: What Providers and Prescribers Need to Know in 2026

Metformin hydrochloride extended-release (Glucophage XR and its generics) is the most widely prescribed first-line oral antidiabetic agent in the United States. Despite the absence of a current national shortage, many providers are fielding calls from patients who cannot locate their metformin ER prescription at local pharmacies. This briefing summarizes the current supply landscape, prescribing considerations, and practical strategies to ensure continuity of care for your patients.

Current Supply Landscape (2026)

As of early 2026, the FDA's drug shortage database does not list metformin extended-release as a current shortage. The major disruption caused by the 2020 NDMA recall has largely resolved, and multiple generic manufacturers have received or maintained FDA approval for metformin ER tablets in 500 mg, 750 mg, and 1000 mg strengths. The original brand-name Glucophage XR was discontinued; all currently dispensed products are generics.

Despite national availability, providers should be aware that pharmacy-level stockouts are common, particularly for specific strengths. Patients on 750 mg tablets may find those harder to source than 500 mg tablets. Urban and suburban pharmacies generally have more reliable stock than rural or small-town pharmacies.

Prescribing Strategies to Maximize Continuity of Care

The following clinical strategies can help minimize prescription-filling disruptions for your patients:

• Write for generic metformin ER: Writing prescriptions as "metformin hydrochloride extended-release" rather than "Glucophage XR" avoids any brand confusion and ensures the pharmacist can fill with any available generic manufacturer's product.
• Enable DAW-0 (dispense as written = 0): Using DAW code 0 on the prescription allows the pharmacist to substitute any FDA-approved generic, maximizing flexibility and availability.
• Keep a bridge prescription ready: Consider providing patients with a backup prescription for immediate-release metformin at the equivalent total daily dose. This allows patients to bridge seamlessly if XR is unavailable, without requiring an additional office call.
• Prescribe 90-day supplies via mail order: For stable patients on long-term maintenance metformin ER, encourage 90-day mail-order fills. Mail-order pharmacies typically maintain more consistent inventory for high-volume generics.
• Document clinical necessity for higher doses: The maximum daily dose of Glucophage XR is 2000 mg. If a patient requires 2550 mg total daily, they will need to supplement with IR metformin for the additional 500-550 mg, as the XR formulation maxes at 2000 mg.

Metformin ER vs. IR: Clinical Differences to Keep in Mind

When patients ask about switching to IR as a bridge, providers should be aware of the following clinical differences:

• GI tolerability: XR has a slower absorption profile, which reduces peak plasma concentrations and GI side effects. Some patients who tolerate XR well will experience diarrhea, nausea, or cramping when switched to IR — particularly initially. Titrating the IR dose gradually (starting at 500 mg BID with meals) can mitigate this.
• Dosing frequency: XR is dosed once daily with the evening meal; IR is typically given 2-3 times daily with meals. Adherence may decrease with the IR formulation for patients accustomed to once-daily dosing.
• Glycemic equivalence: Clinical trial data support that IR and XR at equivalent total daily doses achieve comparable HbA1c reductions.

When to Consider an Alternative Drug Class

If a patient genuinely cannot tolerate any formulation of metformin and there is a supply issue, consider the following alternatives based on clinical profile:

• SGLT-2 inhibitors (empagliflozin, dapagliflozin): Preferred for patients with established cardiovascular disease or CKD (eGFR ≥20). Strong evidence base from EMPA-REG OUTCOME and DECLARE-TIMI trials.
• GLP-1 receptor agonists (semaglutide, liraglutide): First-line preference for patients with obesity, high cardiovascular risk, or significant HbA1c elevation. Excellent HbA1c reduction and meaningful weight loss.
• DPP-4 inhibitors (sitagliptin, linagliptin): Good option for patients who need weight-neutral, low-hypoglycemia-risk oral agents. Linagliptin (Tradjenta) does not require renal dose adjustment — useful in CKD.
• Sulfonylureas (glipizide, glimepiride): Cost-effective for patients prioritizing affordability; note hypoglycemia risk and weight gain potential.

Renal Function Monitoring

Regardless of whether patients are on XR or IR metformin, ensure appropriate renal monitoring:

• Contraindicated when eGFR < 30 mL/min/1.73 m²
• Initiation not recommended when eGFR 30-45 mL/min/1.73 m²
• Assess eGFR at baseline and at least annually; more frequently in patients with CKD risk factors or age > 65
• Hold before iodinated contrast procedures if eGFR 30-60; restart 48h after confirming stable renal function

Patient Resources You Can Share

Providers can direct patients to medfinder.com/providers to learn about medfinder's service, which calls pharmacies on behalf of patients to find which ones have their specific medication in stock. This proactive step can prevent the frustration — and potential health consequences — of a patient arriving at a pharmacy only to be turned away.

Summary for Prescribers

Glucophage XR (generic metformin ER) is not in an active national shortage in 2026, but pharmacy-level availability gaps are a real concern for patients. Prescribing strategies such as writing for generic metformin ER with DAW-0, keeping a bridge prescription for IR metformin on file, and encouraging 90-day mail-order fills can significantly reduce prescription-filling problems. When patients ask about the shortage, point them to our patient-facing shortage update for plain-language guidance.